Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01468194
Other study ID # Gi-04-2011
Secondary ID
Status Completed
Phase N/A
First received October 9, 2011
Last updated November 8, 2011
Start date July 2011
Est. completion date November 2011

Study information

Verified date November 2011
Source University of Giessen
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

In this investigation the researchers explore whether different types of breathing procedures can improve the peripheral oxygen saturation to reduce the risk of becoming a acute mountain sickness or a high altitude pulmonary edema.


Description:

Acute mountain sickness (AMS) is a pathological effect of high altitude on humans caused by acute exposure to low partial pressure of oxygen at high altitude. It commonly occurs above 2500 meters of altitude. AMS appears as a collection of nonspecific symptoms acquired at high altitude or in low air pressure resembling a case of "flu, carbon monoxide poisoning, or a hangover".

It is caused by a drop in pressure and lowering partial pressure of oxygen during increasing altitude. The direct consequence of those changes is a hypoxic pulmonary vasoconstriction (Euler-Lijestrand-mechanism). In addition a rise in pulmonary blood pressure (Hypertonia) can occur so that there is a higher risk of developing a high altitude pulmonary edema (HAPE).

In this investigation the investigators are exploring whether different types of breathing procedures can improve the peripheral oxygen saturation. We are comparing breathing with no regulation with two different procedures of hyperventilation during trekking in different altitudes. Procedure 1 (hyperventilation 1) describes inhalation during one step and exhalation during the next step. Procedure 2 (hyperventilation 2) describes inhalation and exhalation during one step.

The effect of the different breathing procedures can be quantified measuring the peripheral oxygen saturation. In addition the investigators are comparing the breathing rate and the minute ventilation as well as the expiratory end-tidal CO2-partial pressure of the three different breathing procedures.

Furthermore, the investigators are examining the ability to concentrate in order to quantify the effect of AMS on organ functions.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date November 2011
Est. primary completion date October 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Exclusion Criteria:

- acute clinically significant inter-current diseases

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
Breathing procedure 1
inhalation during one step, exhalation during the next step
Breathing procedure 2
inhalation and exhalation during one step

Locations

Country Name City State
Germany University of Giessen Giessen Hessen

Sponsors (2)

Lead Sponsor Collaborator
University of Giessen MVZ für Laboratoriumsmedizin Koblenz

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary change of peripheral oxygen saturation change of peripheral oxygen saturation under different breathing procedures in different altitudes immediate after intervention No
Secondary change of breathing parameters change of breathing parameters under different breathing procedures in different altitudes
breathing rate
minute ventilation
expiratory end-tidal CO2-partial pressure
immediate after intervention No
Secondary change of cognition change of ability of cognition (measured by d2-test) under different breathing procedures in different altitudes immediate after intervention No
See also
  Status Clinical Trial Phase
Completed NCT04111263 - Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude N/A
Completed NCT01842906 - Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) N/A
Completed NCT01536288 - Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Phase 2
Completed NCT00326703 - Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort N/A
Completed NCT06310642 - Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness Phase 4
Not yet recruiting NCT06393998 - CO2 Supplement for Treatment of Acute Mountain Sickness N/A
Completed NCT03561675 - Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Phase 4
Completed NCT00559832 - Prevention of Acute Mountain Sickness by Intermittent Hypoxia N/A
Completed NCT01436383 - Oxidative Stress in Hypobaric Hypoxia N/A
Completed NCT00603122 - Acclimatization Mechanisms During Ascent to 7500m N/A
Completed NCT00664001 - Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness Phase 3
Completed NCT00627965 - Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness Phase 4
Not yet recruiting NCT06145113 - The Effect of Continuous Positive Pressure Ventilation on Symptoms of Acute Mountain Sickness N/A
Recruiting NCT05733338 - The Effects of Intermittent Hypoxia on Acute Hypoxic Injury N/A
Completed NCT01522326 - Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness N/A
Completed NCT03270787 - Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Phase 1/Phase 2
Completed NCT02811016 - Inhaled Budesonide and Acute Mountain Sickness Phase 1
Recruiting NCT00886912 - Training in Hypoxia to Prevent Acute Mountain Sickness N/A
Terminated NCT03956472 - Alternative Treatments in Acute Mountain Sickness N/A
Recruiting NCT03621410 - T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent Phase 2